Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection? by Ruschitzka, Frank & Taddei, Stefano
EDITORIAL
Angiotensin-converting enzyme inhibitors:
first-line agents in cardiovascular protection?
Frank Ruschitzka1* and Stefano Taddei2*
1Division of Cardiology, Zurich University Hospital, Zurich, Switzerland; and 2Department of Internal Medicine, University of Pisa, Pisa 56100, Italy
Online publish-ahead-of-print 1 June 2012
This editorial refers to ‘Angiotensin-converting enzyme
inhibitors reduce mortality in hypertension: a meta-
analysis of randomized clinical trials of renin–angiotensin–
aldosterone system inhibitors involving 158 998 patients’†,
by L.C. van Vark et al., on page 2088
The renin-angiotensin-aldosterone system (RAAS) is essential for
the regulation of blood pressure, cardiovascular and renal function.
Drugs inhibiting the RAAS, particularly angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II receptor blockers
(ARBs), represent the cornerstone of blood pressure control
and considered key components of the modern comprehensive
management of cardiovascular disease.1
In essential hypertension, utilization of ACE inhibitors and ARBs is
based on their effectiveness of lowering blood presssure, high toler-
ability, and the possibility to prevent or reverse target organ damage.
Importantly, controlled clinical trials have demonstrated that these
drugs can reduce cardiovascular morbidity and mortality.1 ACE inhi-
bitors and ARBs, however, differ in their mechanisms of action and
also their effectiveness in reducing clinical, particularly cardiovascu-
lar outcomes, and can therefore not be viewed as interchangeable.
The study by van Vark et al.2 demonstrates the following import-
ant findings: (i) in hypertensive patients, RAAS blockade is asso-
ciated with a significant reduction of all-cause mortality; (ii) but
this benefit is limited to ACE inhibitors and not shared by ARBs.
The present results are not surprising, as they confirm and
extend previous reports indicating that ACE, but not ARBs,
reduce cardiovascular morbidity and mortality.
In a recent meta-analysis of 11 trials (55 050 patients) by Strauss
and Hall that compared ARBs with either placebo or active treat-
ments, only stroke was less likely in patients treated with ARBs
than in those receiving a comparator.3 Their benefit in reducing
stroke notwithstanding, ARBs did not reduce total mortality, but
increased the risk of myocardial infarction (MI) by 8% [95% confi-
dence interval (CI) 1–16%; P ¼ 0.03]. The same authors also con-
ducted parallel analyses for ACE inhibitors,3 demonstrating that
ACE inhibitors decreased overall mortality, cardiovascular death,
and MI by 9, 12, and 14%, respectively. In all cases, and in contrast
to the ARB analyses, the differences were strongly statistically
significant.3
The BPLTTC (Blood Pressure Lowering Treatment Trialists’
Collaboration)4 assessed the blood pressure-dependent and
-independent effects of ACE inhibitors and ARBs on major cardio-
vascular events in patients with hypertension, diabetes, a history of
coronary heart disease, or cerebrovascular disease in a
meta-regression analysis of data from 26 trials involving either
drug class.4 The authors reported similar blood pressure-
dependent effects of ACE inhibitors and ARBs for the risk of
stroke, coronary heart disease, and heart failure. In terms of
blood pressure-independent effects, however, only ACE inhibitors
were associated with a significant additional relative risk reduction
for major coronary disease events of 9% (P ¼ 0.004).
A 2009 meta-analysis of studies included in the BPLTTC analysis
as well as more recent ARB trials provided a database of 100 000
patients from 26 randomized non-heart failure trials of ARBs.5 The
authors observed a 13% reduction in the risk of stroke (P ¼ 0.022),
but a trend toward increased risk of MI, especially when compared
with active treatment (P ¼ 0.06).
A 2011 meta-analysis included all randomized clinical trials com-
paring ARBs with controls (placebo or active treatment)6, with a
total of 37 randomized trials and .147 000 patients. When com-
pared with controls, ARBs were not found to be associated with a
reduction in risk of MI [relative risk (RR) 0.99; 95% CI 0.92–1.07].
There was also no detectable beneficial effect for the outcome of
MI in trials comparing ARBs vs. placebo (RR 0.93; 95% CI 0.81–
1.07), as well as for the outcome of all-cause or cardiovascular
death, despite lower blood pressure with ARBs. When compared
with active treatment, the relative risk of MI with ARBs was 1.04
(95% CI 0.98–1.11), while all-cause and cardiovascular death
were also not reduced.6
The ESH/ESC hypertension guidelines published back in 2007
stated that all classes of antihypertensive drugs should be potentially
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considered as first choice.1 However, guidelines also indicate that
ACE inhibitors have more compelling indications as compared with
ARBs, indirectly supporting a greater beneficial effect of one drug
class as compared with the other. It is worth noting that the only in-
dication specific for ARBs is the cough caused by the ACE inhibitors.
Importantly, ACE inhibitors and ARBs have a different mechan-
ism of action. The inhibition of bradykinin degradation exerted by
ACE inhibitors is often considered an ‘adjunctive’ mechanism with
a limited clinical significance. This view should be partially cor-
rected, since for most ACE inhibitors the ability to block the
ACE site responsible for bradykinin degradation is almost the
same as the activity on the site responsible for the conversion of
angiotensin I into angiotensin II.7 If we consider the potential
effect of bradykinin on the cardiovascular system, it is conceivable
that this pathway might be at least partially responsible for many
effects of ACE inhibitors usually attributed to RAAS blockade. In
hypertensive patients, bradykinin can act on the endothelium by
a nitric oxide (NO)-independent pathway, possibly by the activa-
tion of endothelium-derived hyperpolarizing factors.8 Through
this compensatory mechanism, bradykinin can evoke endothelium-
dependent relaxation or tissue plaminogen activator release,
even in the presence of impaired NO availability, an effect not
shared by other endothelial agonists, including acetylcholine.8 It
is not surprising that in comparative studies in patients with hyper-
tension or coronary artery disease, ACE inhibitors, but not ARBs,
can improve endothelial function in large arteries.9,10
In contrast, ARBs act biologically via a selective blockade of the
angiotensin II type 1 receptor (AT1), leaving the other angiotensin
receptors relatively unopposed. When ARBs were introduced into
clinical practice in 1995, they were expected to lead to similar, if
not greater, blood pressure-lowering effects than ACE inhibitors,
which do not interfere at the receptor level, but rather reduce
the formation of angiotensin II (and the breakdown of bradykinin).
Importantly, as a consequence of the AT1 receptor blockade by
ARBs, angiotensin II levels increase several fold through uncoupling
of the negative feedback mechanism. The increased levels of angio-
tensin II lead in turn to unopposed stimulation of unopposed AT2
receptors. Although it has been proposed that the stimulation of
AT2 receptors mediates vasodilatation and NO release,11 which
would be potentially beneficial, more recent data suggest that
AT2 stimulation may also be involved in promoting vascular
growth, inflammation, and fibrosis.11 Indeed, overexpression of
the AT2 receptor in human cardiac myocytes leads to cardiac
hypertrophy,12 whereas AT2 receptor-deficient mice appear to
be protected against cardiac hypertrophy.13 Interestingly, un-
opposed stimulation of the AT2 receptor by ARBs has been put
forward by Strauss and Hall as a potential explanation for the
so-called sartans paradox, i.e. the increase of MI associated with
the use of ARBs.3
Finally, van Vark et al. correctly comment that ONTARGET and
DETAIL, the only two large-scale clinical trials comparing an ACE
inhibitor vs. an ARB, performed in patients with high cardiovascular
risk and diabetic nephropathy, respectively, showed no difference
between these drug classes. It should however be emphasized
that in both studies telmisartan showed a greater blood pressure
reduction as compared with ramipril in ONTARGET14 and
enalapril in DETAIL.15 Of note, in the recently published Rando-
mized Olmesartan and Diabetes Microalbuminuria Prevention
(ROADMAP) trial,16 the ARB was associated with a delayed
onset of microalbuminuria, but this benefit came at the cost of
an excess of fatal cardiovascular events among patients with pre-
existing coronary heart disease (15 cardiovascular deaths in
patients randomized to olmesartan, compared with a total of
three cardiovascular deaths in the control group).
Since the goal of hypertension management must be the re-
duction of cardiovascular morbidity and total mortality and not
only of surrogates of evidence, such as blood pressure and pro-
teinuria, particular attention should be paid to the choice of
agent in high-risk hypertensive patients. As such, the results of
recent clinical trials and meta-analyses indicating that treatment
with ACE inhibition, but not with ARBs, leads to a statistically sig-
nificant further reduction in mortality in hypertensive patients,
provide further evidence that ACE inhibitors should be consid-
ered the drugs of first choice and ARBs should be restricted
to patients intolerant of ACE inhibitors. Given the high preva-
lence of hypertension in populations worldwide, this may result
in a considerable number of lives saved.
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Huge left atrial thrombus after left atrial appendage occlusion
with a Watchman device
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The feasibility and safety of transcatheter left
atrial appendage occlusion with the WatchmanTM
Device (Atritech Inc., Plymouth, MN, USA) for
stroke prevention in atrial fibrillation (AF) has re-
cently been described. To our knowledge, a case
of huge thrombus formation on the external
surface of this device has not been described so far.
A 78-year-old man with permanent AF suffered
from cerebral haemorrhage while on oral anticoa-
gulation therapy; after 2 months, he was undertaken
to an uneventful left atrial appendage occlusion
using a 33 mm-sized WatchmanTM device. The
patient was discharged on oral anticoagulant, but
the therapeutic target was difficult to be kept.
After 2 months, a transoesophageal echocardio-
gram showed the presence of a big, floating,
stalked thrombus on the atrial side of the Watch-
man device, apparently originating from the
screw’s lodging (Panel A). The finding was con-
firmed by computed tomographic (CT) imaging
(Panel B). Oral anticoagulation therapy was asso-
ciated with low-molecular-weight heparin for 2
more months with an INR target of 3–3.5. The
patient remained completely asymptomatic, without any neurological event. A transoesophageal echocardiogram and CT scan
were then repeated and demonstrated the complete resolution of the left atrial thrombus (Panels C and D). Thus, anti-platelet
therapy was initiated.
It is interesting to point out how the stalked thrombus seems to arise from the screw’s threads, the only part of the device uncov-
ered by nitinol, which could represent a potential pro-thrombotic source.
Panels A and B. Transoesophageal echo and computed tomographic scan of the huge left atrial thrombus on the WatchmanTM
device, respectively. Panels C and D. Transoesophageal echo and computed tomographic scan of thrombus resolution, respectively.
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